Grifols

The ID Core XT is the second molecular assay approved by the FDA for use in transfusion medicine and the first to report genotypes as final results.

The FDA said that pooled testing of donations using a screening test that it has licensed is a sufficient method for complying with its testing regulations.

A combined assay to screen blood donations for HIV and hepatitis viruses and a test for West Nile virus are now cleared to run on the Procleix Panther system. 

Despite the astronomical costs, it may prove challenging to reverse course and discontinue Zika testing according to a commentary article accompanying a NEJM study.

The test is designed to detect 14 of the most prevalent mutations in the gene responsible for the disease.

The assay runs on the Procleix Panther system and detects B. microti, B. duncani, B. divergens, and B. venatorum parasites that can be transmitted by tick bites or blood donation. 

Hologic's CEO said in December that the blood screening business was a drag on the company's growth. 

Hologic CEO Steve MacMillan said that the deal is so compelling that the firm needed to do it now.

Through their arrangement, Singulex has granted Grifols an exclusive license to its single-molecule counting technology for use in blood donor and plasma screening.

Pages

Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.

Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.

Vox explores a proposal to institute a lottery system to award grant funds.

In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.